Expression changes in pre MAPKi treatment and post MAPKi resistance Melanomas

ABSTRACT: Melanoma resistance to MAPK- or T cell checkpoint-targeted therapies represents a major clinical challenge, and treatment failures of MAPK-targeted therapies due to acquired resistance often require salvage immunotherapies. We show that genomic analysis of acquired resistance to MAPK inhibitors revealed key driver genes but failedto adequately account for clinical resistance. From a large-scale comparative analysis of temporal transcriptomes from patient-matched tumor biopsies, we discovered highly recurrent differential expression and signature outputs of c-MET, LEF1 and YAP1 as drivers of acquired MAPK inhibitor resistance. Moreover, integration of gene- and signature-based transcriptomic analysis revealed profound CD8 T cell deficiency detected in half of resistant melanomas in associat

ORGANISM(S): Homo sapiens

SUBMITTER: Roger Lo 

PROVIDER: E-GEOD-65184 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress